AT has received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline and Takeda. KN has received honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Kowa, Mitsubishi Tanabe, Mochida, MSD, Novartis, Novo Nordisk, Ono, Otsuka, and Teijin; research grants from Asahi Kasei, Astellas, Mitsubishi Tanabe, Teijin, Boehringer Ingelheim, Eli Lilly, Novartis, Fuji, and Mochida; and scholarships from Daiichi Sankyo Healthcare, Mitsubishi Tanabe, Teijin, Medtronic, and Bayer.